Zentalis Pharmaceuticals
ZNTL
ZNTL
134 hedge funds and large institutions have $2.32B invested in Zentalis Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 59 increasing their positions, 27 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
22% more funds holding
Funds holding: 110 → 134 (+24)
4.15% more ownership
Funds ownership: 112.79% → 116.94% (+4.2%)
Holders
134
Holding in Top 10
5
Calls
$4.45M
Puts
$1.08M
Top Buyers
| 1 | +$134M | |
| 2 | +$103M | |
| 3 | +$46.9M | |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$30.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$22.5M |
Top Sellers
| 1 | -$41M | |
| 2 | -$30.2M | |
| 3 | -$18.9M | |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$17.2M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$16.8M |